Kaimen Rigor reviewed
Rigor-Reviewed Manuscript
Colchicine in patients with acute ischaemic stroke or transient ischaemic attack (CHANCE-3): multicentre, double blind, randomised, placebo controlled trial.
Li J, Meng X, Shi FD, Jing J, Gu HQ, Jin A, Jiang Y, Li H, Johnston SC, Hankey GJ, Easton JD, Chang L, Shi P, Wang L, Zhuang X, Li H, Zang Y, Zhang J, Sun Z, Liu D, Li Y, Yang H, Zhao J, Yu W, Wang A, Pan Y, Lin J, Xie X, Jin WN, Li S, Niu S, Wang Y, Zhao X, Li Z, Liu L, Zheng H, Wang Y, CHANCE-3 Investigators
Paper source
Colchicine in patients with acute ischaemic stroke or transient ischaemic attack (CHANCE-3): multicentre, double blind, randomised, placebo controlled trial.
Embed this Rigor badge
Links back to this Kaimen Rigor review.
Alpha1 Editorial
This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026
Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →